Development of 4H-pyridopyrimidines: a class of selective bacterial protein synthesis inhibitors

Organic and Medicinal Chemistry Letters - Tập 2 Số 1 - 2012
Joseph W. Guiles1, András Toró1, Urs A. Ochsner1, James M. Bullard1
1Replidyne, Inc., Louisville, CO, USA

Tóm tắt

Abstract Background We have identified a series of compounds that inhibit protein synthesis in bacteria. Initial IC50's in aminoacylation/translation (A/T) assays ranged from 3 to14 μM. This series of compounds are variations on a 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-ol scaffold (e.g., 4H-pyridopyrimidine). Methods Greater than 80 analogs were prepared to investigate the structure-activity relationship (SAR). Structural modifications included changes in the central ring and substituent modifications in its periphery focusing on the 2- and 6-positions. An A/T system was used to determine IC50 values for activity of the analogs in biochemical assays. Minimum inhibitory concentrations (MIC) were determined for each analog against cultures of Enterococcus faecalis, Moraxella catarrhalis, Haemophilus influenzae, Streptococcus pneumoniae, Staphylococcus aureus, Escherichia coli tolC mutants and E. coli modified with PMBN. Results Modifications to the 2-(pyridin-2-yl) ring resulted in complete inactivation of the compounds. However, certain modifications at the 6-position resulted in increased antimicrobial potency. The optimized compounds inhibited the growth of E. faecalis, M. catarrhalis, H. influenzae, S. pneumoniae, S. aureus, E. coli tolC, mutants and E. coli modified with PMBN with MIC values of 4, ≤ 0.12, 1, 2, 4, 1, 1 μg/ml, respectively. IC50 values in biochemical assay were reduced to mid-nanomolar range. Conclusion 4H-pyridopyrimidine analogs demonstrate broad-spectrum inhibition of bacterial growth and modification of the compounds establishes SAR.

Từ khóa


Tài liệu tham khảo

Overcoming Antimicrobial Resistance World Health Organization; 2000.

Hermann T: Drugs targeting the ribosome. Curr Opin Struct Biol 2005, 15: 355–366. 10.1016/j.sbi.2005.05.001

Knowles DJ, Foloppe N, Matassova NB, Murchie AI: The bacterial ribosome, a promising focus for structure-based drug design. Curr Opin Pharmacol 2002, 2: 501–506. 10.1016/S1471-4892(02)00205-9

Bryskier A: Antimicrobial agents: antibacterials and antifungals. ASM Press, Washington, DC; 2005.

Cundiffe E: The ribosome. In Structure, function, and evolution. Edited by: Hill WE, Dahlberg A, Garrett RA, Moore PB, Schlessinger D, Warner JR. Am Soc Microbiol, Washington, DC; 1990:479–490.

Ribble W, Hill WE, Jarvis TC, Ochsner UA, Guiles JW, Janjic N, Bullard JM: Discovery and analysis of 4 H -Pyridopyrimidines, a class of selective bacterial protein synthesis inhibitors. Antimicrob Agents Chemother 2010, 54: 4648–4657. 10.1128/AAC.00638-10

National Committee for Clinical Laboratory Standards: Methods for determining bactericidal activity of antimicrobial agents: approved guide line M26-A. NCCLS, Wayne, PA; 2002.

National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically: approved standard M7-A6. NCCLS, Wayne, PA; 2003.

Ochsner UA, Young CL, Stone KC, Dean FB, Janjic N, Critchley IA: Mode of action and biochemical characterization of REP8839, a novel inhibitor of methionyl-tRNA synthetase. Antimicrob Agents Chemother 2005, 49: 4253–4262. 10.1128/AAC.49.10.4253-4262.2005

Thông tin
Thông tin xuất bản

Organic and Medicinal Chemistry Letters

Tập 2 Số 1

Thông tin tác giả